Skip to main content
. 2011 Mar 7;29(22):3085–3096. doi: 10.1200/JCO.2010.33.2312

Fig 2.

Fig 2.

A 38-year-old man with BRAF-mutant melanoma and miliary, subcutaneous metastatic deposits. Photographs were taken (A) before initiation of PLX4032, (B) after 15 weeks of therapy with PLX4032, and (C) after relapse, after 23 weeks of therapy.